Literature DB >> 30592623

The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.

Xiaorong Huang1, Chunxiang Wu2, Yangshin Park2,3,4, Xuwei Long1, Quyen Q Hoang2,3,4, Jingling Liao1,2,5.   

Abstract

Parkinson disease-associated mutations within the GTPase domain Ras of complex proteins (ROC) of leucine rich repeat kinase 2 (LRRK2) result in an abnormal over-activation of its kinase domain. However, the mechanisms involved remain unclear. Recent study has shown that LRRK2 G-domain cycles between monomeric and dimeric conformations upon binding to GTP or guanosine diphosphate, and that the Parkinson's disease (PD)-associated R1441C/G/H mutations impair the G-domain monomer-dimer dynamics and trap the G-domain in a constitutive monomeric conformation. That led us to question whether other disease-associated mutations in G-domain would also affect its conformation. Here, we report that another PD-associated N1437H mutation also impairs its monomer-dimer conformational dynamics and GTPase activity. In contrast with mutations at R1441, ROCN1437H was found to be locked in a stable dimeric conformation in solution and its GTPase activity was ∼4-fold lower than that of the wild-type. Furthermore, the N1437H mutation reduced the GTP binding affinity by ∼2.5-fold when compared with other pathogenic G-domain mutations. Moreover, ROCN1437H was found to have a slower GTP dissociation rate, indicating that N1437H might interrupt the nucleotide exchange cycle. Taken together, our data support that conformational dynamics is important for LRRK2 GTPase activity and that the N1437H mutation impairs GTPase activity by locking the ROC domain in a persistently dimeric state.-Huang, X., Wu, C., Park, Y., Long, X., Hoang, Q. Q., Liao, J. The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.

Entities:  

Keywords:  GTPase activity; disease-associated mutation; monomer-dimer

Mesh:

Substances:

Year:  2018        PMID: 30592623      PMCID: PMC6988866          DOI: 10.1096/fj.201802031R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  34 in total

Review 1.  Small GTP-binding proteins.

Authors:  Y Takai; T Sasaki; T Matozaki
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

2.  Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant.

Authors:  Veronique Daniëls; Renée Vancraenenbroeck; Bernard M H Law; Elisa Greggio; Evy Lobbestael; Fangye Gao; Marc De Maeyer; Mark R Cookson; Kirsten Harvey; Veerle Baekelandt; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

3.  Structure of the G60A mutant of Ras: implications for the dominant negative effect.

Authors:  Bradley Ford; Karlheinz Skowronek; Sean Boykevisch; Dafna Bar-Sagi; Nicolas Nassar
Journal:  J Biol Chem       Date:  2005-05-05       Impact factor: 5.157

4.  Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.

Authors:  Giambattista Guaitoli; Francesco Raimondi; Bernd K Gilsbach; Yacob Gómez-Llorente; Egon Deyaert; Fabiana Renzi; Xianting Li; Adam Schaffner; Pravin Kumar Ankush Jagtap; Karsten Boldt; Felix von Zweydorf; Katja Gotthardt; Donald D Lorimer; Zhenyu Yue; Alex Burgin; Nebojsa Janjic; Michael Sattler; Wim Versées; Marius Ueffing; Iban Ubarretxena-Belandia; Arjan Kortholt; Christian Johannes Gloeckner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

Review 5.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

Review 6.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Nat Rev Neurosci       Date:  2010-11-19       Impact factor: 34.870

7.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology.

Authors:  Z K Wszolek; R F Pfeiffer; Y Tsuboi; R J Uitti; R D McComb; A J Stoessl; A J Strongosky; A Zimprich; B Müller-Myhsok; M J Farrer; T Gasser; D B Calne; D W Dickson
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

8.  The next epidemic.

Authors:  Gregory A Petsko
Journal:  Genome Biol       Date:  2006-05-31       Impact factor: 13.583

Review 9.  L'RRK de Triomphe: a solution for LRRK2 GTPase activity?

Authors:  Jonathon Nixon-Abell; Daniel C Berwick; Kirsten Harvey
Journal:  Biochem Soc Trans       Date:  2016-12-15       Impact factor: 5.407

10.  GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.

Authors:  Alice Biosa; Alzbeta Trancikova; Laura Civiero; Liliane Glauser; Luigi Bubacco; Elisa Greggio; Darren J Moore
Journal:  Hum Mol Genet       Date:  2012-12-13       Impact factor: 6.150

View more
  8 in total

1.  Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics.

Authors:  Chun-Xiang Wu; Jingling Liao; Yangshin Park; Xylena Reed; Victoria A Engel; Neo C Hoang; Yuichiro Takagi; Steven M Johnson; Mu Wang; Mark Federici; R Jeremy Nichols; Ruslan Sanishvili; Mark R Cookson; Quyen Q Hoang
Journal:  J Biol Chem       Date:  2019-02-22       Impact factor: 5.157

Review 2.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

3.  Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo.

Authors:  Souvarish Sarkar; Farah Bardai; Abby L Olsen; Kelly M Lohr; Ying-Yi Zhang; Mel B Feany
Journal:  Mol Neurodegener       Date:  2021-05-24       Impact factor: 14.195

Review 4.  Modelling the functional genomics of Parkinson's disease in Caenorhabditis elegans: LRRK2 and beyond.

Authors:  Rachael J Chandler; Susanna Cogo; Patrick A Lewis; Eva Kevei
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

5.  LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains.

Authors:  Jui-Hung Weng; Phillip C Aoto; Robin Lorenz; Jian Wu; Sven H Schmidt; Jascha T Manschwetus; Pallavi Kaila-Sharma; Steve Silletti; Sebastian Mathea; Deep Chatterjee; Stefan Knapp; Friedrich W Herberg; Susan S Taylor
Journal:  PLoS Biol       Date:  2022-02-22       Impact factor: 8.029

Review 6.  Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease.

Authors:  Laura J Smith; Chiao-Yin Lee; Elisa Menozzi; Anthony H V Schapira
Journal:  Front Neurol       Date:  2022-08-12       Impact factor: 4.086

Review 7.  Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.

Authors:  Paweł Turski; Iwona Chaberska; Piotr Szukało; Paulina Pyska; Łukasz Milanowski; Stanisław Szlufik; Monika Figura; Dorota Hoffman-Zacharska; Joanna Siuda; Dariusz Koziorowski
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

Review 8.  Molecular Pathways Involved in LRRK2-Linked Parkinson's Disease: A Systematic Review.

Authors:  Ailyn Irvita Ravinther; Hemaniswarri Dewi Dewadas; Shi Ruo Tong; Chai Nien Foo; Yu-En Lin; Cheng-Ting Chien; Yang Mooi Lim
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.